Gelteq Limited Ordinary Shares (GELS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gelteq Limited Ordinary Shares (GELS) has a cash flow conversion efficiency ratio of -0.020x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-302.15K) by net assets ($15.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gelteq Limited Ordinary Shares (GELS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Gelteq Limited Ordinary Shares - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Gelteq Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gelteq Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gelteq Limited Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
333D Ltd
AU:T3D
|
0.084x |
|
Throgmorton Trust Plc
LSE:THRG
|
0.018x |
|
VITAL BATTERY METALS INC
F:C0O
|
N/A |
|
Buff Technologies Ltd
TA:BUFT
|
1.599x |
|
Quantum Genomics SA
PA:ALQGC
|
3.110x |
|
Hansa Investment Company Ltd
LSE:HANA
|
0.007x |
|
SIV Capital Ltd
AU:SIV
|
0.020x |
|
Harworth Group PLC
LSE:HWG
|
-0.109x |
Annual Cash Flow Conversion Efficiency for Gelteq Limited Ordinary Shares (2023–2025)
The table below shows the annual cash flow conversion efficiency of Gelteq Limited Ordinary Shares from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see GELS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $15.80 Million | $-5.52 Million | -0.349x | -393.22% |
| 2024-06-30 | $15.11 Million | $-1.07 Million | -0.071x | +25.35% |
| 2023-06-30 | $18.66 Million | $-1.77 Million | -0.095x | -- |
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.